[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Dako North America Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":163},{"warningLetters":4,"total":162},[5,32,53,76,98,118,141],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},2337,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022\">BergaMet North America LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jay Decker\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BergaMet North America LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6445 S. Tenaya Way Suite B110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89113-1989\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:orders@bergametna.com\"> orders@bergametna.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636315\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jay Decker:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\u003Cbr>\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-inflammatory”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Reduces cholesterol”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n\u003Cbr>\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;On a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\u003Cbr>\n&nbsp; o “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\u003Cbr>\n&nbsp; o “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\u003Cbr>\n&nbsp; o You also endorsed the following responses to your post by liking them:\u003Cbr>\n&nbsp; &nbsp; 􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Yes!! Mine went down 38 points.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n\u003Cbr>\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jay Decker\n\nBergaMet North America LLC\n\n6445 S. Tenaya Way Suite B110\n\nLas Vegas, NV 89113-1989\n\nUnited States\n\norders@bergametna.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636315\n\nDear Mr. Jay Decker:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\n\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\n\n“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\n\n“Anti-inflammatory”\n\n“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\n\n“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\n\n“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\n\nOn your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\n\n“Reduces cholesterol”\n\n“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\n\nOn your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\n\n“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\n\nYour websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\n\n“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\n\nOn your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\n\nOn a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\n\no “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\n\no “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\n\no “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\n\no You also endorsed the following responses to your post by liking them:\n\n􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\n\n“Yes!! Mine went down 38 points.”\n\nYour Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","BergaMet North America LLC","bergamet-north-america-llc-636315-11142022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022","2026-10-26T08:08:03.414177+00:00","Warning Letter","Issued","2022-11-17","636315","Dietary SupplementsDrugs","Mr. Jay Decker","2026-08-20T01:25:33.357+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":19,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":20,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":52,"medical_device_id":20,"response_letter_date":20},2127,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-27T05:00:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022\">North American Diagnostics, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Elizabeth A. Lashinsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>618 Ridgewood Ave., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holly Hill\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32117\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ealash52@gmail.com\"> ealash52@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 643203\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDecember 27, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lashinsky:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong> Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70.\u003C\u002Fstrong> Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fstrong> Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80.\u003C\u002Fstrong> Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong> Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a).\u003C\u002Fstrong> Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong> Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b).\u003C\u002Fstrong> Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\u003Cbr>\n\u003Cbr>\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to\u003C\u002Fstrong> COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 643203\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nBlake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-%20emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nElizabeth A. Lashinsky\n\nRecipient Title\n\nOwner\n\nNorth American Diagnostics, LLC\n\n618 Ridgewood Ave., Suite 100\n\nHolly Hill, FL 32117\n\nUnited States\n\nealash52@gmail.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 643203\n\nDecember 27, 2022\n\nDear Ms. Lashinsky:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\n\nOur inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\n\nThis inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a). Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\n\n2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70. Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\n\n3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\n\n4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80. Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\n\n5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\n\n6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a). Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\n\n7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\n\n8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b). Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\n\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\n\nWe reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\n\nYour firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 643203 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n______________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","North American Diagnostics, LLC","north-american-diagnostics-llc-643203-12272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022","2026-10-26T08:09:34.512211+00:00","2023-04-18","643203","Medical Devices","Elizabeth A. Lashinsky","2026-08-20T01:09:41.813+00:00","VIA Electronic Mail","2022-12-27",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":20,"letter_url":66,"updated_at":67,"action_type":23,"case_status":24,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":20,"issuing_office":59,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":74,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},139,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-14T04:00:00Z\">05\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026\">GC America, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-76\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph T. Talanges\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GC America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3737 West 127th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Talanges:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including those for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to ensure components were suitable for use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum, meets specifications in the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system records show that you only performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling requirements and acceptance criteria. According to your management, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug batches with inadequately tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> from 2023 through 2025.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for \u003C\u002Fem>\u003Cstrong>(b)(4) \u003C\u002Fstrong>\u003Cem>Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination before using them to manufacture your drug products. This includes, but is not limited to, testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its appropriate identity prior to use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not perform all testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per USP, and you commit to sending a sample of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on drug products released from 2023 to 2025 and to establishing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing SOP.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a detailed procedure explaining how you will assess your \u003Cstrong>(b)(4)\u003C\u002Fstrong> against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fp>\u003Cp>• The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fp>\u003Cp>• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>• A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fp>\u003Cp>• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fp>\u003Cp>• Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system qualification report.\u003C\u002Fp>\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the USP monograph.\u003C\u002Fp>\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\u003Cp>• A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\u003Cbr>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for \u003Cstrong>(b)(4)\u003C\u002Fstrong> consisted of a single batch tested for \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter affixed to a laptop by a sticker used for processing \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter test results. In addition, the data from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\u003C\u002Fp>\u003Cp>Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\u003C\u002Fp>\u003Cp>In your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\u003Cbr>• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003Cbr>\u003Cbr>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>Kennerly K. Chapman -S\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Digitally signed by Kennerly K. Chapman -S\u003Cbr>Date: 2026.05.14 15:58:58 -04'00'\u003Cbr>Office of Manufacturing Quality Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-76\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph T. Talanges\n\nRecipient Title\n\nPresident & Chief Operating Officer\n\nGC America, Inc.\n\n3737 West 127th Street\n\nAlsip, IL 60803\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 14, 2026\nWARNING LETTER\n\nDear Mr. Talanges:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products, including those for (b)(4). Your firm failed to ensure components were suitable for use in manufacturing your drug products.\n(b)(4) Used as a Component in Drug Products\nYou did not adequately demonstrate your (b)(4), at a minimum, meets specifications in the United States Pharmacopeia (USP) (b)(4) monograph. For example, your (b)(4) system records show that you only performed (b)(4) testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing (b)(4) sampling requirements and acceptance criteria. According to your management, you manufactured approximately (b)(4) finished drug batches with inadequately tested (b)(4) from 2023 through 2025.\nProducts Containing Ingredients at Risk for (b)(4) Contamination\nYou also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of (b)(4) contamination before using them to manufacture your drug products. This includes, but is not limited to, testing (b)(4) to determine its appropriate identity prior to use in manufacturing your drug products.\nIdentity testing for (b)(4) and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nIn your response, you acknowledge you do not perform all testing of (b)(4) per USP, and you commit to sending a sample of your (b)(4) to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient (b)(4) testing on drug products released from 2023 to 2025 and to establishing a (b)(4) testing SOP.\nYour response is inadequate. You do not provide a detailed procedure explaining how you will assess your (b)(4) against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\nWithout adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\nIn response to this letter, provide:\n• A procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\n• The current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n• A comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\n• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\n• Your (b)(4) system qualification report.\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of (b)(4) of the USP monograph.\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n• A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\nYour firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for (b)(4) consisted of a single batch tested for (b)(4) at (b)(4) degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\nWithout an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\nSee FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\nIn your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\nYour response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\nIn response to this letter, provide:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYour quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the (b)(4) meter affixed to a laptop by a sticker used for processing (b)(4) meter test results. In addition, the data from the (b)(4) meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\nYour QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\nIn your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\nYour response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\n\nSincerely,\nKennerly K. Chapman -S\nFrancis Godwin\nDirector\nDigitally signed by Kennerly K. Chapman -S\nDate: 2026.05.14 15:58:58 -04'00'\nOffice of Manufacturing Quality Office of Compliance\nCenter for Drug Evaluation and Research","GC America, Inc.","gc-america-inc-727602-05142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026","2026-10-26T08:08:44.827832+00:00","2026-05-26","727602","Drugs Over-the-Counter Drugs","Mr. Joseph T. Talanges","2026-08-19T04:39:48.869+00:00","Via Email Return Receipt Requested","320-26-76","2026-05-14",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":65,"fei_number":20,"letter_url":88,"updated_at":89,"action_type":23,"case_status":24,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":20,"issuing_office":59,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":20,"reference_number":96,"action_taken_date":97,"medical_device_id":20,"response_letter_date":20},398,[79,80,81,59,82,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-08T05:00:00Z\">12\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdarmerica-llc-716152-12082025\">Darmerica, LLC\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-24\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kyle Hamza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Darmerica, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4380 Oakes Road, Suite 800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Davie\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33314\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Khamza@darmerica.com\"> Khamza@darmerica.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:kyle@darmerica.com\"> kyle@darmerica.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-24\u003C\u002Fp>\u003Cp>December 8, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Hamza:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Darmerica, LLC, FEI 3012389174, at 4380 Oakes Road, Suite 800, Davie, from March 3 through 19, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations, including deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). Your introduction or delivery for introduction into interstate commerce of adulterated drugs is a violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>In addition, Darmerica has distributed drugs that are misbranded within the meaning of section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), due to false or misleading labeling, and section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), due to labeling without adequate directions for use. Darmerica also distributed drugs that are misbranded within the meaning of section 502(o) because they were not properly listed in accordance with section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207. Your receipt in interstate commerce of misbranded drugs, and your introduction or delivery for introduction into interstate commerce of misbranded drugs, violate sections 301(c) and 301(a) of the FD&amp;C Act, 21 U.S.C. 331(c) and 331(a), respectively.&nbsp;\u003C\u002Fp>\u003Cp>In addition, failure to provide listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your April 7, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Adulterated Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure of your quality unit to exercise its responsibility to ensure that APIs manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA investigators observed that your firm lacked adequate quality unit (QU) oversight for the receipt of materials, repackaging, relabeling, and related controls for your APIs, which causes the drugs you distribute to be adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. The introduction of such drugs into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). Examples of failures of your QU are listed below.\u003C\u002Fp>\u003Cp>\u003Cem>1. Failure to Ensure that Your System for Evaluating Suppliers was Adequate\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA’s inspection revealed that your firm received API from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Darmerica also served as the firm’s U.S. agent starting in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Darmerica remained listed as the U.S. agent for \u003Cstrong>(b)(4)\u003C\u002Fstrong> until \u003Cstrong>(b)(4)\u003C\u002Fstrong> de-registered its establishment in FDA’s registration system on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The first documented shipment from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to Darmerica was in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the last shipment to Darmerica was in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to the FDA inspection at \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You initially approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a supplier in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and requalified the firm in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As an example of a failure of your QU, as part of this qualification process, \u003Cstrong>(b)(4)\u003C\u002Fstrong> completed a vendor survey that asked whether it had had any regulatory inspections. In \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> answered in the affirmative, stating that an inspection by FDA resulted in a “satisfactory” outcome even though the U.S. FDA had not inspected the firm. However, the vendor survey completed by \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated that it had not had any regulatory inspections. There is no indication that your firm investigated this discrepancy prior to requalifying \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Additionally, your quality agreements with \u003Cstrong>(b)(4)\u003C\u002Fstrong> included the provision of ongoing stability data generated per a stability protocol and annual stability data for appropriate packaging configuration. However, during an FDA inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA investigators observed that there were no stability chambers nor stability and reserve samples available. In addition, the facility did not provide any stability data for at least one lot of each API manufactured in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to our investigator. This encompasses the timeframe in which you received drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> under the terms of the quality agreements that, consistent with your procedures, required adequate stability data as part of supplier qualification. If \u003Cstrong>(b)(4)\u003C\u002Fstrong> was unable to and\u002For did not provide stability data to your firm as required under your \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality agreement, qualifying the firm as a supplier again in \u003Cstrong>(b)(4)\u003C\u002Fstrong> would indicate another failure of your system for evaluating suppliers.\u003C\u002Fp>\u003Cp>Your response to the Form FDA 483 is inadequate. You indicate that your firm’s failure to verify \u003Cstrong>(b)(4)\u003C\u002Fstrong> responses to a vendor survey “is not a failure for Darmerica to qualify all other manufacturers” as per your SOP. However, your firm qualified a supplier that gave inconsistent responses about its inspectional history and was not equipped to provide stability data for its products as required by your quality agreement. Your firm then imported and distributed drugs from that supplier despite its apparent failure to comply with the terms of your quality agreement. As noted below, based on our inspection of records at your facility and a review of FDA import data, FDA is also aware of non-compliance among other firms that have previously supplied APIs to your firm.\u003C\u002Fp>\u003Cp>\u003Cem>2. Failure to Adequately Investigate Quality-Related Complaints and Recalls\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm did not adequately investigate customer complaints. Specifically, your QU failed to extend product quality complaint investigations to other lots of APIs potentially associated with the root cause, failure, or deviation. For example, you were made aware by \u003Cstrong>(b)(4)\u003C\u002Fstrong> on May 9, 2023, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on July 10, 2023, that \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, contained black chunks that did not appear consistent with previous lots of the drug. You distributed API from this lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> times to \u003Cstrong>(b)(4)\u003C\u002Fstrong> different customers. After receiving the complaint, your firm returned the remaining amount of lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> in Darmerica’s inventory to the API manufacturer but did not contact your additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> customers or investigate further whether they had also received complaints about any potential contamination.\u003C\u002Fp>\u003Cp>In your response, you state that the Darmerica’s investigation found that the particles were part of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> shedding during the manufacturing process and that the supplier classified them as “technically unavoidable particles” that did not affect product quality. You conveyed to the two customers that complained about the product that your supplier suggested that the particles be removed manually. Notably, however, your QU decided to return your remaining impacted inventory of lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the manufacturer without further investigation.\u003C\u002Fp>\u003Cp>Your response is inadequate. Though your firm conveyed the supplier’s confirmation of the issue to the two customers who initially submitted complaints, you failed to contact your other customers to determine whether they had experienced a similar problem. Your response states that “[a]ll other customers who bought the same product did not have any issue with the product,” but this cannot be confirmed if your firm did not contact those customers to investigate the matter. Further, your supplier’s response is indicative of a fundamental lack of understanding of CGMP, as the proposal for customers to manually remove the \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles does not satisfy the requirement for drugs to meet the quality and purity characteristics they purport to possess.&nbsp;\u003C\u002Fp>\u003Cp>FDA is concerned that Darmerica accepted this supplier’s response as compliant with CGMP. There is no indication that your firm followed up on this supplier’s response any further or considered whether it was appropriate to continue purchasing API from a firm that displayed such a fundamental lack of understanding of CGMP. Notably, you distributed to clients a different lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured by the same supplier, that you received prior to the second complaint on July 10, 2023 and before the manufacturer could have corrected the issues with the equipment used in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API.\u003C\u002Fp>\u003Cp>In addition, your recall procedure lacked clarity on how to handle supplier recalls. For example, your firm quarantined all \u003Cstrong>(b)(4)\u003C\u002Fstrong> products immediately after receiving a notice on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, of the firm’s voluntary recall of drugs from the U.S. market after FDA documented violations at this facility. All remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> material in stock at your firm was returned to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there is no documented evidence that you informed your downstream customers of \u003Cstrong>(b)(4)\u003C\u002Fstrong> voluntary recall of drugs from the U.S. market or of the firm’s violative inspection. Your quality manager said clients were contacted via telephone, but there is no documented evidence that you contacted the numerous customers that received drugs manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. None of the APIs distributed to customers were returned to Darmerica. We acknowledge that your response included an updated recall procedure that requires future client contact to be documented.\u003C\u002Fp>\u003Cp>\u003Cem>3. Failure to Ensure Adequate Pre-Release Testing of APIs\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm lacked adequate QU oversight for the relabeling and repackaging of your API. Specifically, your firm failed to perform adequate testing and approve the results for your APIs prior to their release and distribution. For example, your firm released APIs for distribution prior to your QU completing its review. According to your records, your firm received and distributed a \u003Cstrong>(b)(4)\u003C\u002Fstrong> API, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Though a sample was sent to your third-party testing laboratory for analysis, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> API occurred prior to your firm’s own QU release of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> API on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and before the certificate of analysis (COA) was reviewed and authorized by your third-party lab on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you state that due to patients’ need of the medication, the lot was released and distributed before the third-party lab tests were completed. This response is inadequate because without adequate testing, you cannot demonstrate that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before release for use in production to assure adequate quality. This violation is of heightened importance given FDA’s documented compliance concerns related to API manufacturers in your supply chain.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed list containing API name, manufacturer name, manufacturer lot number, date of entry, import entry number, port of entry, order number, quantity, grade, usage, date of receipt, and information regarding the first date distributed, such as customer name and address, for all drugs received by your firm within three years from the date of this letter. If an import entry number is not available, that should be noted and provide the shipping records that you have (e.g. invoice, bill of lading, waybill, etc.).\u003C\u002Fli>\u003Cli>The following information, based on a comprehensive review of your material system:\u003Cbr>o Whether you have notified your customers that they received adulterated drugs from your firm. If you have not notified any customer who received adulterated drugs from Darmerica, notify them, and provide a copy of that notification in your response. The notification should include lot identification, recommended actions, and customer acknowledgement.\u003Cbr>o Evaluating all manufacturers of materials to determine if they are reliable and appropriately qualified.\u003Cbr>o An assessment of all materials to determine whether they are consistently of acceptable quality.\u003C\u002Fli>\u003Cli>Supplier qualification procedures implemented for new API manufacturers and supply chain verification measures taken by your firm, including the selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>A detailed list of the manufacturers that have been evaluated for approval and\u002For qualification within the past three years from the date of this letter. This list should include, but not be limited to manufacturer name, address, FDA Establishment Identifier (FEI), point of contact and email address, current status (e.g., acceptable, unacceptable, disqualified, or hold), date approved, and whether a quality agreement is in place with the manufacturer. Any manufacturers that had their status changed from acceptable to unacceptable or disqualified should note the date this occurred and reason why.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systemic corrective action and preventive action (CAPA) to remediate the vendor qualification program and prevent use of unsuitable material suppliers.\u003C\u002Fli>\u003Cli>A full reconciliation of any drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as for all firms or drugs currently on FDA import alerts, to determine if you have any remaining drugs from those firms in your possession. Up to date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fli>\u003Cli>A list of investigations initiated within the past three years for deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall complaint system, including a comprehensive list of all complaints where you returned drugs to the manufacturer, as well as information on whether you contacted your customers to investigate each complaint and the date of that contact, if applicable. If you have not contacted your customers to investigate each complaint, contact them, and provide a copy of that contact in your response.\u003C\u002Fli>\u003Cli>Provide a detailed action plan to remediate your complaint system. Your action plan should include, but not be limited to,\u003Cbr>o Significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures.\u003Cbr>o Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each lot and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligations to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As discussed below, your firm received and distributed misbranded drugs in interstate commerce, which are prohibited acts under sections 301(c) and 301(a), respectively.\u003C\u002Fp>\u003Cp>\u003Cem>1. Distribution of drugs lacking adequate directions for use\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You received retatrutide from your supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Retatrutide is a GLP-1 API that is not identified as an active ingredient in any drug approved by FDA. You distributed this API to pharmacies seeking to compound human drugs under section 503A of the FD&amp;C Act even though retatrutide is not eligible for use in compounding under section 503A.\u003C\u002Fp>\u003Cp>Additional APIs that you distribute or distributed to compounders seeking to operate under section 503A of the FD&amp;C Act that are ineligible for use in human drug compounding under sections 503A include: dapoxetine hydrochloride, 2-methoxyestradiol (2ME2), tesofensine, FGL acetate aka [GLP-1]-FGL peptide acetate, thymogen, buserelin acetate, elamipretide (SS-31) acetate, larazotide acetate, and cagrilintide acetate.\u003C\u002Fp>\u003Cp>The labeling of these drugs fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&amp;C Act. Such APIs are not exempt from section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), under FDA regulations (see 21 C.F.R. Part 201), and, as noted, they are intended for use in a compounded drug that would be ineligible for the exemptions provided by section 503A of the FD&amp;C Act, 21 U.S.C. 353a. The introduction or delivery for introduction into interstate commerce of these drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>We have reviewed your May 1, 2025, email submitted in response to our April 2, 2025, teleconference, in which you discuss your distribution of the APIs retatrutide base and cagrilintide acetate. We acknowledge your statement, “Darmerica has ceased importing\u002Fdistributing Retatrutide and delisted the NDC registration from FDA’s CDER website. As discussed during the April 02, 2025, meeting with FDA, Darmerica stopped the importation and distribution of Cagrilintide and is in the process of delisting the NDC registration from the FDA’s CDER website.” Your corrective actions related to retatrutide base and cagrilintide acetate appear adequate.\u003C\u002Fp>\u003Cp>\u003Cem>2. Receipt of drugs whose labeling is false or misleading\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Under section 502(a) of the FD&amp;C Act, a drug is misbranded if its labeling is false or misleading in any particular. Your firm received multiple shipments of API that you knew to be mislabeled. Since March 2022, GLP-1 APIs were shipped to your firm as “custom peptide,” omitting the drug name. Because of this material omission, the labeling of the drug is false or misleading, causing the drug to be misbranded under section 502(a). We note that you acknowledged that this occurred, indicating it was to prevent theft of high demand products and to address the country’s export requirements for specific peptides.\u003C\u002Fp>\u003Cp>\u003Cem>3. Receipt of drugs from establishments not duly registered with FDA and failure to provide listing information to FDA\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Section 510 of the FD&amp;C Act, 21 U.S.C. 360, and 21 CFR Part 207 set forth the requirements for establishment registration and drug listing. Under section 502(o), a drug is misbranded if, among other things, it was manufactured in an establishment not duly registered under section 510, or if it was not included in a list required by section 510(j). Under section 301(a), it is a prohibited act to introduce or deliver for introduction into interstate commerce any drug that is misbranded, and under section 301(c), it is a prohibited act to receive in interstate commerce a drug that is misbranded. In addition, failure to provide listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>You received and distributed drugs from facilities that were not duly registered with FDA. For example, you provided an incorrect address for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the March 2025 inspection; that same address was listed in the firm’s establishment registration. An internet search of this firm’s address indicated that it was a residential building and not an API manufacturing facility. After placing the facility on import alert, FDA physically visited the address and confirmed that it is an empty apartment in a residential building. According to the firm’s registered point of contact, the firm had gone out of business the year before; the point of contact did not know who manufactured or distributed GLP-1 APIs that you received and distributed to your customers for use in GLP-1 drug products administered to patients in the United States. This supplier was not duly registered with FDA under section 510 of the FD&amp;C Act, causing its drugs to be misbranded within the meaning of section 502(o).\u003C\u002Fp>\u003Cp>In addition, you distributed drugs for which you did not provide listing information under section 510(j). Specifically, under section 510(j)(1)(C) of the FD&amp;C Act, 21 U.S.C 360(j)(1)(C), and 21 CFR 207.49(a)(4), a registrant must include in drug listings the name and quantity of each API in their listed drugs. In at least 23 of your drug listings, the proprietary name, non-proprietary name, and\u002For product labeling do not match the active ingredient provided in the Structured Product Labeling (SPL). For example, in your listing for the drug “Hexarelin Acetate” (NDC 71052-621), you list the active ingredient as peptide B27PD in the SPL. Similarly, in the listing for the drug API “Elamipretide (SS-31) Acetate” (NDC 71052-907), you list the active ingredient as peptide B27PD in the SPL. Therefore, “Hexarelin Acetate” and “Elamipretide Acetate” are not listed in accordance with section 510(j)(1)(C) of the FD&amp;C Act, 21 U.S.C 360(j)(1)(C), and 21 CFR 207.49(a)(4), rendering them misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C 352(o). The introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). Failure to provide listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all products manufactured at your establishment and those that you repackage\u002Frelabel comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found in the FDA Electronic Drug Registration and Listing Instructions at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Felectronic-drug-registration-and-listing-system-edrls\u002Felectronic-drug-registration-and-listing-instructions.\u003C\u002Fp>\u003Cp>\u003Cstrong>Other Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Suppliers in Your Supply Chain with a History of Non-Compliance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that a review of records collected from an inspection at your facility and a review of FDA import data demonstrated that FDA has, in the past, put more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the manufacturers who supply your APIs on import alert because the drugs they manufacture appear to be adulterated under section 501 of the FD&amp;C Act. Drugs from multiple API manufacturers used by Darmerica were listed on import alerts, including Import Alert 66-40 (IA 66-40) for the manufacturer’s apparent failure to conform with CGMP within the meaning of section 501(a)(2)(B) and Import Alert 66-79 (IA 66-79) for refusing to permit access to or copying of any record as required by section 704(a). To understand whether Darmerica has received any or introduced additional adulterated drugs in interstate commerce, we are requesting information regarding timing of receipt and distribution of drugs from the more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> facilities listed below.\u003C\u002Fp>\u003Cp>\u003Cem>Darmerica suppliers with drugs listed on IA 66-40 for suppliers’ failure to comply with CGMP:\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For manufacturers whose drugs are placed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alerts appear to be adulterated. You are responsible for ensuring that the drugs you receive and distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding the import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>\u003Cem>Darmerica suppliers with drugs from manufacturers listed on IA 66-79 for refusing to permit access to or copying of any record as required by section 704(a).\u003C\u002Fem>\u003C\u002Fp>\u003Cp>All drugs from the following facilities appear to be adulterated in that they have been manufactured, processed, packed, or held in a facility and the owner, operator, or agent of such facility delays, denies, or limits an inspection, or refuses to permit entry or inspection. These firms were approved by your firm prior to the March inspection:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>The following firms approved by your firm failed to respond to the agency’s records request during or after your 2025 inspection:\u003C\u002Fem>\u003C\u002Fp>\u003Cp>After the FDA inspection, you stated that you improved your supplier qualification program. Yet the following firms that have supplied drugs to Darmerica have been found to be violative since the FDA inspection:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response, provide the following information:\u003C\u002Fp>\u003Cul>\u003Cli>Whether you distributed the drugs from a facility listed above during the time period after the supplier was found to have engaged in the violative activity identified and before any resolution (e.g., removal from an IA).\u003C\u002Fli>\u003Cli>For lots of API received and distributed by Darmerica during the relevant timeframe, indicate whether you have notified your customers that they received adulterated drugs from your firm. If you have not notified any customer who received adulterated drug API from Darmerica, notify them. Include lot identification and recommended actions in your notifications. In your response to this warning letter, provide a copy of that notification and customer acknowledgement.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Destruction of Incoming Labels\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our investigators observed your firm destroying original labels during API receipt. FDA is concerned that this practice may obscure supply chain information that may be necessary during CGMP investigations, complaints, or other matters.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Pre-shipment Samples\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, it was observed that your firm was inappropriately relying on results of quality testing of pre-shipment samples that were shipped directly from the API manufacturer to your third-party laboratory for analysis. For example, your third-party testing laboratory received a sample of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> API, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacturer’s lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> from an API manufacturer for testing on February 27, 2025. However, this same API was not received at your facility until March 3, 2025, four days later. Samples used for the sake of identity testing and evaluation of other quality attributes are to be taken at your facility from containers after receipt from the API manufacturer to ensure they are representative of the API in question and account for the conditions of transport to your facility.\u003C\u002Fp>\u003Cp>For more information about sampling and testing of representative samples to ensure suitability prior to use in repackaging or distribution to customers see FDA’s current guidance document, \u003Cem>Questions and Answers on Current Good Manufacturing Practice Requirements | Control of Components and Drug Product Containers and Closures\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fguidances-drugs\u002Fquestions-and-answers-current-good-manufacturing-practice-requirements-control-components-and-drug.\u003C\u002Fp>\u003Cp>\u003Cstrong>Importation of Unlisted Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 510(j)(1) of the FD&amp;C Act and 21 CFR 207.41(a), a registrant must list each drug that it manufactures, repacks, relabels, or salvages for commercial distribution. As of July 28, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong> FDA registered manufacturers that identify Darmerica as an importer do not list any drugs with FDA. In numerous instances, Darmerica has attempted to import drugs that are not listed with FDA into the United States. You are responsible for ensuring that the drugs you import are properly listed with FDA.\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012389174 and ATTN: Marva Taylor.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman, JD\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-24\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kyle Hamza\n\nRecipient Title\n\nVice President\n\nDarmerica, LLC\n\n4380 Oakes Road, Suite 800\n\nDavie, FL 33314\n\nUnited States\n\nKhamza@darmerica.com\n\nkyle@darmerica.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-24\nDecember 8, 2025\nDear Mr. Hamza:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Darmerica, LLC, FEI 3012389174, at 4380 Oakes Road, Suite 800, Davie, from March 3 through 19, 2025.\nThis warning letter summarizes significant violations, including deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). Your introduction or delivery for introduction into interstate commerce of adulterated drugs is a violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nIn addition, Darmerica has distributed drugs that are misbranded within the meaning of section 502(a) of the FD&C Act, 21 U.S.C. 352(a), due to false or misleading labeling, and section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), due to labeling without adequate directions for use. Darmerica also distributed drugs that are misbranded within the meaning of section 502(o) because they were not properly listed in accordance with section 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207. Your receipt in interstate commerce of misbranded drugs, and your introduction or delivery for introduction into interstate commerce of misbranded drugs, violate sections 301(c) and 301(a) of the FD&C Act, 21 U.S.C. 331(c) and 331(a), respectively.\nIn addition, failure to provide listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nThese violations are described in more detail below.\nWe reviewed your April 7, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\nA. Adulterated Drugs\nFailure of your quality unit to exercise its responsibility to ensure that APIs manufactured at your facility are in compliance with CGMP.\nFDA investigators observed that your firm lacked adequate quality unit (QU) oversight for the receipt of materials, repackaging, relabeling, and related controls for your APIs, which causes the drugs you distribute to be adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act. The introduction of such drugs into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Examples of failures of your QU are listed below.\n1. Failure to Ensure that Your System for Evaluating Suppliers was Adequate\nFDA’s inspection revealed that your firm received API from (b)(4), FEI (b)(4). Darmerica also served as the firm’s U.S. agent starting in (b)(4). Darmerica remained listed as the U.S. agent for (b)(4) until (b)(4) de-registered its establishment in FDA’s registration system on (b)(4). The first documented shipment from (b)(4) to Darmerica was in (b)(4), and the last shipment to Darmerica was in (b)(4), (b)(4) prior to the FDA inspection at (b)(4). You initially approved (b)(4) as a supplier in (b)(4) and requalified the firm in (b)(4). As an example of a failure of your QU, as part of this qualification process, (b)(4) completed a vendor survey that asked whether it had had any regulatory inspections. In (b)(4), (b)(4) answered in the affirmative, stating that an inspection by FDA resulted in a “satisfactory” outcome even though the U.S. FDA had not inspected the firm. However, the vendor survey completed by (b)(4) in (b)(4) stated that it had not had any regulatory inspections. There is no indication that your firm investigated this discrepancy prior to requalifying (b)(4).\nAdditionally, your quality agreements with (b)(4) included the provision of ongoing stability data generated per a stability protocol and annual stability data for appropriate packaging configuration. However, during an FDA inspection of (b)(4) in (b)(4), FDA investigators observed that there were no stability chambers nor stability and reserve samples available. In addition, the facility did not provide any stability data for at least one lot of each API manufactured in (b)(4) to our investigator. This encompasses the timeframe in which you received drugs from (b)(4) under the terms of the quality agreements that, consistent with your procedures, required adequate stability data as part of supplier qualification. If (b)(4) was unable to and\u002For did not provide stability data to your firm as required under your (b)(4) quality agreement, qualifying the firm as a supplier again in (b)(4) would indicate another failure of your system for evaluating suppliers.\nYour response to the Form FDA 483 is inadequate. You indicate that your firm’s failure to verify (b)(4) responses to a vendor survey “is not a failure for Darmerica to qualify all other manufacturers” as per your SOP. However, your firm qualified a supplier that gave inconsistent responses about its inspectional history and was not equipped to provide stability data for its products as required by your quality agreement. Your firm then imported and distributed drugs from that supplier despite its apparent failure to comply with the terms of your quality agreement. As noted below, based on our inspection of records at your facility and a review of FDA import data, FDA is also aware of non-compliance among other firms that have previously supplied APIs to your firm.\n2. Failure to Adequately Investigate Quality-Related Complaints and Recalls\nOur inspection also revealed that your firm did not adequately investigate customer complaints. Specifically, your QU failed to extend product quality complaint investigations to other lots of APIs potentially associated with the root cause, failure, or deviation. For example, you were made aware by (b)(4) on May 9, 2023, and (b)(4) on July 10, 2023, that (b)(4) lot (b)(4) manufactured by (b)(4), FEI (b)(4), contained black chunks that did not appear consistent with previous lots of the drug. You distributed API from this lot (b)(4) times to (b)(4) different customers. After receiving the complaint, your firm returned the remaining amount of lot (b)(4) in Darmerica’s inventory to the API manufacturer but did not contact your additional (b)(4) customers or investigate further whether they had also received complaints about any potential contamination.\nIn your response, you state that the Darmerica’s investigation found that the particles were part of the (b)(4) shedding during the manufacturing process and that the supplier classified them as “technically unavoidable particles” that did not affect product quality. You conveyed to the two customers that complained about the product that your supplier suggested that the particles be removed manually. Notably, however, your QU decided to return your remaining impacted inventory of lot (b)(4) to the manufacturer without further investigation.\nYour response is inadequate. Though your firm conveyed the supplier’s confirmation of the issue to the two customers who initially submitted complaints, you failed to contact your other customers to determine whether they had experienced a similar problem. Your response states that “[a]ll other customers who bought the same product did not have any issue with the product,” but this cannot be confirmed if your firm did not contact those customers to investigate the matter. Further, your supplier’s response is indicative of a fundamental lack of understanding of CGMP, as the proposal for customers to manually remove the (b)(4) particles does not satisfy the requirement for drugs to meet the quality and purity characteristics they purport to possess.\nFDA is concerned that Darmerica accepted this supplier’s response as compliant with CGMP. There is no indication that your firm followed up on this supplier’s response any further or considered whether it was appropriate to continue purchasing API from a firm that displayed such a fundamental lack of understanding of CGMP. Notably, you distributed to clients a different lot of (b)(4), lot (b)(4), manufactured by the same supplier, that you received prior to the second complaint on July 10, 2023 and before the manufacturer could have corrected the issues with the equipment used in the manufacture of (b)(4) API.\nIn addition, your recall procedure lacked clarity on how to handle supplier recalls. For example, your firm quarantined all (b)(4) products immediately after receiving a notice on (b)(4), of the firm’s voluntary recall of drugs from the U.S. market after FDA documented violations at this facility. All remaining (b)(4) material in stock at your firm was returned to (b)(4). However, there is no documented evidence that you informed your downstream customers of (b)(4) voluntary recall of drugs from the U.S. market or of the firm’s violative inspection. Your quality manager said clients were contacted via telephone, but there is no documented evidence that you contacted the numerous customers that received drugs manufactured by (b)(4). None of the APIs distributed to customers were returned to Darmerica. We acknowledge that your response included an updated recall procedure that requires future client contact to be documented.\n3. Failure to Ensure Adequate Pre-Release Testing of APIs\nYour firm lacked adequate QU oversight for the relabeling and repackaging of your API. Specifically, your firm failed to perform adequate testing and approve the results for your APIs prior to their release and distribution. For example, your firm released APIs for distribution prior to your QU completing its review. According to your records, your firm received and distributed a (b)(4) API, (b)(4), lot (b)(4) on (b)(4). Though a sample was sent to your third-party testing laboratory for analysis, the (b)(4) distribution of the (b)(4) API occurred prior to your firm’s own QU release of the (b)(4) API on (b)(4) and before the certificate of analysis (COA) was reviewed and authorized by your third-party lab on (b)(4).\nIn your response, you state that due to patients’ need of the medication, the lot was released and distributed before the third-party lab tests were completed. This response is inadequate because without adequate testing, you cannot demonstrate that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before release for use in production to assure adequate quality. This violation is of heightened importance given FDA’s documented compliance concerns related to API manufacturers in your supply chain.\nIn response to this letter, provide:\nA detailed list containing API name, manufacturer name, manufacturer lot number, date of entry, import entry number, port of entry, order number, quantity, grade, usage, date of receipt, and information regarding the first date distributed, such as customer name and address, for all drugs received by your firm within three years from the date of this letter. If an import entry number is not available, that should be noted and provide the shipping records that you have (e.g. invoice, bill of lading, waybill, etc.).\nThe following information, based on a comprehensive review of your material system:\no Whether you have notified your customers that they received adulterated drugs from your firm. If you have not notified any customer who received adulterated drugs from Darmerica, notify them, and provide a copy of that notification in your response. The notification should include lot identification, recommended actions, and customer acknowledgement.\no Evaluating all manufacturers of materials to determine if they are reliable and appropriately qualified.\no An assessment of all materials to determine whether they are consistently of acceptable quality.\nSupplier qualification procedures implemented for new API manufacturers and supply chain verification measures taken by your firm, including the selection, qualification, and disqualification provisions.\nA detailed list of the manufacturers that have been evaluated for approval and\u002For qualification within the past three years from the date of this letter. This list should include, but not be limited to manufacturer name, address, FDA Establishment Identifier (FEI), point of contact and email address, current status (e.g., acceptable, unacceptable, disqualified, or hold), date approved, and whether a quality agreement is in place with the manufacturer. Any manufacturers that had their status changed from acceptable to unacceptable or disqualified should note the date this occurred and reason why.\nBased on a thorough review, provide a summary of your systemic corrective action and preventive action (CAPA) to remediate the vendor qualification program and prevent use of unsuitable material suppliers.\nA full reconciliation of any drugs from (b)(4), as well as for all firms or drugs currently on FDA import alerts, to determine if you have any remaining drugs from those firms in your possession. Up to date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nA list of investigations initiated within the past three years for deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.\nA comprehensive assessment of your overall complaint system, including a comprehensive list of all complaints where you returned drugs to the manufacturer, as well as information on whether you contacted your customers to investigate each complaint and the date of that contact, if applicable. If you have not contacted your customers to investigate each complaint, contact them, and provide a copy of that contact in your response.\nProvide a detailed action plan to remediate your complaint system. Your action plan should include, but not be limited to,\no Significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures.\no Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each lot and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the deviations identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligations to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nB. Misbranded Drugs\nAs discussed below, your firm received and distributed misbranded drugs in interstate commerce, which are prohibited acts under sections 301(c) and 301(a), respectively.\n1. Distribution of drugs lacking adequate directions for use\nYou received retatrutide from your supplier, (b)(4), FEI (b)(4). Retatrutide is a GLP-1 API that is not identified as an active ingredient in any drug approved by FDA. You distributed this API to pharmacies seeking to compound human drugs under section 503A of the FD&C Act even though retatrutide is not eligible for use in compounding under section 503A.\nAdditional APIs that you distribute or distributed to compounders seeking to operate under section 503A of the FD&C Act that are ineligible for use in human drug compounding under sections 503A include: dapoxetine hydrochloride, 2-methoxyestradiol (2ME2), tesofensine, FGL acetate aka [GLP-1]-FGL peptide acetate, thymogen, buserelin acetate, elamipretide (SS-31) acetate, larazotide acetate, and cagrilintide acetate.\nThe labeling of these drugs fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. Such APIs are not exempt from section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), under FDA regulations (see 21 C.F.R. Part 201), and, as noted, they are intended for use in a compounded drug that would be ineligible for the exemptions provided by section 503A of the FD&C Act, 21 U.S.C. 353a. The introduction or delivery for introduction into interstate commerce of these drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nWe have reviewed your May 1, 2025, email submitted in response to our April 2, 2025, teleconference, in which you discuss your distribution of the APIs retatrutide base and cagrilintide acetate. We acknowledge your statement, “Darmerica has ceased importing\u002Fdistributing Retatrutide and delisted the NDC registration from FDA’s CDER website. As discussed during the April 02, 2025, meeting with FDA, Darmerica stopped the importation and distribution of Cagrilintide and is in the process of delisting the NDC registration from the FDA’s CDER website.” Your corrective actions related to retatrutide base and cagrilintide acetate appear adequate.\n2. Receipt of drugs whose labeling is false or misleading\nUnder section 502(a) of the FD&C Act, a drug is misbranded if its labeling is false or misleading in any particular. Your firm received multiple shipments of API that you knew to be mislabeled. Since March 2022, GLP-1 APIs were shipped to your firm as “custom peptide,” omitting the drug name. Because of this material omission, the labeling of the drug is false or misleading, causing the drug to be misbranded under section 502(a). We note that you acknowledged that this occurred, indicating it was to prevent theft of high demand products and to address the country’s export requirements for specific peptides.\n3. Receipt of drugs from establishments not duly registered with FDA and failure to provide listing information to FDA\nSection 510 of the FD&C Act, 21 U.S.C. 360, and 21 CFR Part 207 set forth the requirements for establishment registration and drug listing. Under section 502(o), a drug is misbranded if, among other things, it was manufactured in an establishment not duly registered under section 510, or if it was not included in a list required by section 510(j). Under section 301(a), it is a prohibited act to introduce or deliver for introduction into interstate commerce any drug that is misbranded, and under section 301(c), it is a prohibited act to receive in interstate commerce a drug that is misbranded. In addition, failure to provide listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nYou received and distributed drugs from facilities that were not duly registered with FDA. For example, you provided an incorrect address for (b)(4), during the March 2025 inspection; that same address was listed in the firm’s establishment registration. An internet search of this firm’s address indicated that it was a residential building and not an API manufacturing facility. After placing the facility on import alert, FDA physically visited the address and confirmed that it is an empty apartment in a residential building. According to the firm’s registered point of contact, the firm had gone out of business the year before; the point of contact did not know who manufactured or distributed GLP-1 APIs that you received and distributed to your customers for use in GLP-1 drug products administered to patients in the United States. This supplier was not duly registered with FDA under section 510 of the FD&C Act, causing its drugs to be misbranded within the meaning of section 502(o).\nIn addition, you distributed drugs for which you did not provide listing information under section 510(j). Specifically, under section 510(j)(1)(C) of the FD&C Act, 21 U.S.C 360(j)(1)(C), and 21 CFR 207.49(a)(4), a registrant must include in drug listings the name and quantity of each API in their listed drugs. In at least 23 of your drug listings, the proprietary name, non-proprietary name, and\u002For product labeling do not match the active ingredient provided in the Structured Product Labeling (SPL). For example, in your listing for the drug “Hexarelin Acetate” (NDC 71052-621), you list the active ingredient as peptide B27PD in the SPL. Similarly, in the listing for the drug API “Elamipretide (SS-31) Acetate” (NDC 71052-907), you list the active ingredient as peptide B27PD in the SPL. Therefore, “Hexarelin Acetate” and “Elamipretide Acetate” are not listed in accordance with section 510(j)(1)(C) of the FD&C Act, 21 U.S.C 360(j)(1)(C), and 21 CFR 207.49(a)(4), rendering them misbranded under section 502(o) of the FD&C Act, 21 U.S.C 352(o). The introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Failure to provide listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nIt is your responsibility to ensure that all products manufactured at your establishment and those that you repackage\u002Frelabel comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found in the FDA Electronic Drug Registration and Listing Instructions at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Felectronic-drug-registration-and-listing-system-edrls\u002Felectronic-drug-registration-and-listing-instructions.\nOther Concerns\nDrug Suppliers in Your Supply Chain with a History of Non-Compliance\nWe note that a review of records collected from an inspection at your facility and a review of FDA import data demonstrated that FDA has, in the past, put more than (b)(4) of the manufacturers who supply your APIs on import alert because the drugs they manufacture appear to be adulterated under section 501 of the FD&C Act. Drugs from multiple API manufacturers used by Darmerica were listed on import alerts, including Import Alert 66-40 (IA 66-40) for the manufacturer’s apparent failure to conform with CGMP within the meaning of section 501(a)(2)(B) and Import Alert 66-79 (IA 66-79) for refusing to permit access to or copying of any record as required by section 704(a). To understand whether Darmerica has received any or introduced additional adulterated drugs in interstate commerce, we are requesting information regarding timing of receipt and distribution of drugs from the more than (b)(4) facilities listed below.\nDarmerica suppliers with drugs listed on IA 66-40 for suppliers’ failure to comply with CGMP:\n(b)(4)\nFor manufacturers whose drugs are placed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alerts appear to be adulterated. You are responsible for ensuring that the drugs you receive and distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding the import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nDarmerica suppliers with drugs from manufacturers listed on IA 66-79 for refusing to permit access to or copying of any record as required by section 704(a).\nAll drugs from the following facilities appear to be adulterated in that they have been manufactured, processed, packed, or held in a facility and the owner, operator, or agent of such facility delays, denies, or limits an inspection, or refuses to permit entry or inspection. These firms were approved by your firm prior to the March inspection:\n(b)(4)\nThe following firms approved by your firm failed to respond to the agency’s records request during or after your 2025 inspection:\nAfter the FDA inspection, you stated that you improved your supplier qualification program. Yet the following firms that have supplied drugs to Darmerica have been found to be violative since the FDA inspection:\n(b)(4)\nIn your response, provide the following information:\nWhether you distributed the drugs from a facility listed above during the time period after the supplier was found to have engaged in the violative activity identified and before any resolution (e.g., removal from an IA).\nFor lots of API received and distributed by Darmerica during the relevant timeframe, indicate whether you have notified your customers that they received adulterated drugs from your firm. If you have not notified any customer who received adulterated drug API from Darmerica, notify them. Include lot identification and recommended actions in your notifications. In your response to this warning letter, provide a copy of that notification and customer acknowledgement.\nDestruction of Incoming Labels\nOur investigators observed your firm destroying original labels during API receipt. FDA is concerned that this practice may obscure supply chain information that may be necessary during CGMP investigations, complaints, or other matters.\nUse of Pre-shipment Samples\nDuring our inspection, it was observed that your firm was inappropriately relying on results of quality testing of pre-shipment samples that were shipped directly from the API manufacturer to your third-party laboratory for analysis. For example, your third-party testing laboratory received a sample of a (b)(4) API, (b)(4), manufacturer’s lot (b)(4) from an API manufacturer for testing on February 27, 2025. However, this same API was not received at your facility until March 3, 2025, four days later. Samples used for the sake of identity testing and evaluation of other quality attributes are to be taken at your facility from containers after receipt from the API manufacturer to ensure they are representative of the API in question and account for the conditions of transport to your facility.\nFor more information about sampling and testing of representative samples to ensure suitability prior to use in repackaging or distribution to customers see FDA’s current guidance document, Questions and Answers on Current Good Manufacturing Practice Requirements | Control of Components and Drug Product Containers and Closures at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fguidances-drugs\u002Fquestions-and-answers-current-good-manufacturing-practice-requirements-control-components-and-drug.\nImportation of Unlisted Drugs\nUnder section 510(j)(1) of the FD&C Act and 21 CFR 207.41(a), a registrant must list each drug that it manufactures, repacks, relabels, or salvages for commercial distribution. As of July 28, 2025, (b)(4) FDA registered manufacturers that identify Darmerica as an importer do not list any drugs with FDA. In numerous instances, Darmerica has attempted to import drugs that are not listed with FDA into the United States. You are responsible for ensuring that the drugs you import are properly listed with FDA.\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nThis letter notifies you of our findings and provides you an opportunity to address them. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012389174 and ATTN: Marva Taylor.\nSincerely,\n\u002FS\u002F\nJill P. Furman, JD\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research","Darmerica, LLC","darmerica-llc-716152-12082025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdarmerica-llc-716152-12082025","2026-10-26T08:08:21.42837+00:00","2025-12-23","716152","Drugs","Mr. Kyle Hamza","2026-08-19T07:19:34.742+00:00","VIA EMAIL WITH READ RECEIPT","320-26-24","2025-12-08",{"id":99,"raw":100,"subject":14,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":109,"fei_number":20,"letter_url":110,"updated_at":111,"action_type":23,"case_status":24,"posted_date":112,"marcs_cms_no":113,"product_type":92,"closeout_date":20,"issuing_office":104,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":20,"reference_number":20,"action_taken_date":117,"medical_device_id":20,"response_letter_date":20},3352,[101,102,103,104,14,13,13,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-21T04:00:00Z\">04\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021\">North American Hirudin Biotech Products Inc.\u003C\u002Fa>","Office of Regulatory Affairs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zengxun An\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Hirudin Biotech Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2531 Broadway, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Everett\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Regulatory Affairs\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 21, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 613103\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. An:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hirudin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the http:\u002F\u002Fushirudin.com\u002F website:\u003Cbr>\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “Is hirudin a potential therapeutic agent for arthritis?”\u003C\u002Fp>\n\n\u003Cp>• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\u003Cbr>\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\u003Cbr>\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Hirudin Tablet:\u003Cbr>\n&nbsp; &nbsp; o [N]aturally lowers cholesterol content from your blood system.\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood.\u003Cbr>\n&nbsp; &nbsp; o [D]issolve the . . . cholesterol in your blood . . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Red 65\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fbuyred65.com\u002F:\u003Cbr>\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\u003C\u002Fp>\n\n\u003Cp>• “[N]aturally lowers cholesterol content from your blood system.”\u003C\u002Fp>\n\n\u003Cp>• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\u003Cbr>\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\u003C\u002Fp>\n\n\u003Cp>• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Red 65:\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\u003Cbr>\n&nbsp; &nbsp; o [D]issolve . . . cholesterol in your blood. . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\u003Cbr>\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\u003C\u002Fp>\n\n\u003Cp>• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nZengxun An\n\nRecipient Title\n\nPresident\n\nNorth American Hirudin Biotech Products Inc.\n\n2531 Broadway, Suite A\n\nEverett, WA 98201\n\nUnited States\n\nIssuing Office:\n\nOffice of Regulatory Affairs\n\nUnited States\n\nApril 21, 2021\n\nIn reply, refer to CMS 613103\n\nWARNING LETTER\n\nDear Mr. An:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nHirudin\n\nOn the http:\u002F\u002Fushirudin.com\u002F website:\n\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\n\n• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “Is hirudin a potential therapeutic agent for arthritis?”\n\n• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nOn the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\n\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\n\n• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\nOn the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\n\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Hirudin Tablet:\n\no [N]aturally lowers cholesterol content from your blood system.\n\no Blood-thinning . . . help normalize the blood sugar level in your blood.\n\no [D]issolve the . . . cholesterol in your blood . . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nRed 65\n\nOn the website http:\u002F\u002Fbuyred65.com\u002F:\n\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\n\n• “[N]aturally lowers cholesterol content from your blood system.”\n\n• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\n\n• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\n\nOn the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\n\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\n\n• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Red 65:\n\no Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\n\no [D]issolve . . . cholesterol in your blood. . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\n• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\n\nOn the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\n\nOn the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\n\n• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\n\nOn the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\n\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\n\n• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\n\n• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nYour “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","North American Hirudin Biotech Products Inc.","north-american-hirudin-biotech-products-inc-613103-04212021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021","2026-10-26T08:09:34.567247+00:00","2021-05-18","613103","Zengxun An","2026-08-20T03:08:12.347+00:00","Overnight Delivery","2021-04-21",{"id":119,"raw":120,"subject":125,"body_html":127,"body_text":128,"firm_name":129,"letter_id":130,"created_at":19,"fei_number":20,"letter_url":131,"updated_at":132,"action_type":23,"case_status":133,"posted_date":134,"marcs_cms_no":135,"product_type":92,"closeout_date":136,"issuing_office":137,"recipient_name":138,"body_fetched_at":139,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":140,"medical_device_id":20,"response_letter_date":20},2238,[121,122,123,124,125,13,126,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-18T05:00:00Z\">11\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022\">North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","Compounding Pharmacy\u002FAdulterated Drug Products","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-01272026\">\u003Ctime datetime=\"2026-03-20T04:00:00Z\">03\u002F20\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Justin K. Graves\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1736 North Greenville Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richardson\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75081-1808\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 11\u002F18\u002F2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case #: 642792\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Graves,\u003C\u002Fp>\n\n\u003Cp>From March 1, 2022, to March 10, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, located at 1736 North Greenville Avenue, Richardson, TX 75081. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on March 10, 2022. FDA acknowledges receipt of your facility’s response, dated March 30, 2022, as well as your subsequent correspondence. FDA acknowledges that your firm initiated a voluntary recall of drug products that are intended to be sterile on April 5, 2022. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA [21 U.S.C. § 353a] describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\n\u003Cbr>\n\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your firm used a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the purposes of product sterilization that was not appropriate for pharmaceutical use and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing was inadequate. Therefore, you do not have assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was integral throughout use.\u003C\u002Fp>\n\n\u003Cp>2. Your firm did not adequately disinfect materials or supplies during transfer from the ISO 8 cleanroom into higher classification areas.\u003C\u002Fp>\n\n\u003Cp>3. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>5. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. Regarding your response related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. In your response to Observation 1 of the Form FDA 483, we acknowledge your firm’s statement that you have regained supply of and resumed use of previously unavailable \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “immediate use sterile subcutaneous injectable compounding” at your facility. However, you did not provide sufficient evidence of the corrective actions, such as purchase orders, current batch records (i.e., formula work sheets), or \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedures for the newly acquired \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. Regarding the pink residue on the ceiling, vents, and walls in your production area as described in Observation 5 of the Form FDA 483, you provided your revised SOP, 02-CPCP-12 \u003Cem>Non-Sterile Hazardous Compound – Hormone Only&nbsp;\u003C\u002Fem>and committed to “attempting a deep scrubbing of the room.” It is unclear if this cleaning was attempted and\u002For effective to remediate this observation or if your revised procedures have prevented reoccurrence.\u003C\u002Fp>\n\n\u003Cp>3. In your response to Observation 7 of the Form FDA 483, we acknowledge your firm’s statement that, “Moving forward, when smoke studies are conducted, footage from video will record, in detail, the dynamic compounding of sterile compounding in a PEC.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such as an updated smoke study protocol or an updated detailed report, and\u002For video.\u003C\u002Fp>\n\n\u003Cp>4. In your response to Observation 8 of the Form FDA 483, we acknowledge your firm’s statement that, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such updated media fill protocol or results.\u003C\u002Fp>\n\n\u003Cp>In addition, from review of the evidence collected during the inspection, your October 26, 2021, \u003Cem>Environmental Monitoring Report\u003C\u002Fem> lists your action level for the ISO 5 area as&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fm\u003Csup>3\u003C\u002Fsup> for “Air Test” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fplate for “Surface Test.” Please note that any microbial contamination in the ISO 5 area is a serious concern and considered an insanitary condition. If any ISO 5 recovery occurs, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could have been affected.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case number 642792.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Shawn Larson, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov and Shawn.Larson@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Dr. Larson via phone at 214-253-5216 or email at Shawn.Larson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Justin K. Graves\n\nRecipient Title\n\nVice President\n\nNorth American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\n\n1736 North Greenville Avenue\n\nRichardson, TX 75081-1808\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 11\u002F18\u002F2022\n\nCase #: 642792\n\nWARNING LETTER\n\nDear Mr. Graves,\n\nFrom March 1, 2022, to March 10, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, located at 1736 North Greenville Avenue, Richardson, TX 75081. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on March 10, 2022. FDA acknowledges receipt of your facility’s response, dated March 30, 2022, as well as your subsequent correspondence. FDA acknowledges that your firm initiated a voluntary recall of drug products that are intended to be sterile on April 5, 2022. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA [21 U.S.C. § 353a] describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n\n1. Your firm used a (b)(4) for the purposes of product sterilization that was not appropriate for pharmaceutical use and the (b)(4) testing was inadequate. Therefore, you do not have assurance that the (b)(4) was integral throughout use.\n\n2. Your firm did not adequately disinfect materials or supplies during transfer from the ISO 8 cleanroom into higher classification areas.\n\n3. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\n4. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n\n5. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. Regarding your response related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\n1. In your response to Observation 1 of the Form FDA 483, we acknowledge your firm’s statement that you have regained supply of and resumed use of previously unavailable (b)(4) for “immediate use sterile subcutaneous injectable compounding” at your facility. However, you did not provide sufficient evidence of the corrective actions, such as purchase orders, current batch records (i.e., formula work sheets), or (b)(4) testing procedures for the newly acquired (b)(4).\n\n2. Regarding the pink residue on the ceiling, vents, and walls in your production area as described in Observation 5 of the Form FDA 483, you provided your revised SOP, 02-CPCP-12 Non-Sterile Hazardous Compound – Hormone Only and committed to “attempting a deep scrubbing of the room.” It is unclear if this cleaning was attempted and\u002For effective to remediate this observation or if your revised procedures have prevented reoccurrence.\n\n3. In your response to Observation 7 of the Form FDA 483, we acknowledge your firm’s statement that, “Moving forward, when smoke studies are conducted, footage from video will record, in detail, the dynamic compounding of sterile compounding in a PEC.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such as an updated smoke study protocol or an updated detailed report, and\u002For video.\n\n4. In your response to Observation 8 of the Form FDA 483, we acknowledge your firm’s statement that, “(b)(4).” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such updated media fill protocol or results.\n\nIn addition, from review of the evidence collected during the inspection, your October 26, 2021, Environmental Monitoring Report lists your action level for the ISO 5 area as (b)(4) cfu\u002Fm3 for “Air Test” and (b)(4) cfu\u002Fplate for “Surface Test.” Please note that any microbial contamination in the ISO 5 area is a serious concern and considered an insanitary condition. If any ISO 5 recovery occurs, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could have been affected.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\n\nYour written notification should refer to case number 642792.\n\nPlease electronically submit your reply, on company letterhead, to Shawn Larson, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov and Shawn.Larson@fda.hhs.gov\n\nIf you have questions regarding the contents of this letter, you may contact Dr. Larson via phone at 214-253-5216 or email at Shawn.Larson@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n__________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.","North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding","north-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022","2026-10-26T08:09:34.465242+00:00","Closed Out","2023-01-24","642792","2026-03-20","Division of Pharmaceutical Quality Operations II","Mr. Justin K. Graves","2026-08-20T01:18:42.458+00:00","2022-11-18",{"id":142,"raw":143,"subject":148,"body_html":149,"body_text":150,"firm_name":151,"letter_id":152,"created_at":153,"fei_number":20,"letter_url":154,"updated_at":155,"action_type":23,"case_status":24,"posted_date":156,"marcs_cms_no":20,"product_type":92,"closeout_date":20,"issuing_office":157,"recipient_name":158,"body_fetched_at":159,"delivery_method":160,"recipient_title":20,"reference_number":20,"action_taken_date":161,"medical_device_id":20,"response_letter_date":20},1837,[144,145,146,147,148,13,13,13],"\u003Ctime datetime=\"2023-09-19T13:20:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-01T04:00:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national\">Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maria S. LeMay-Bey, Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Isaiah Orton-Bey, Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16136 W. 7 Mile Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Detroit\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48235\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Moorherbs13@gmail.com\"> Moorherbs13@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS Case #655674\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 1, 2023\u003Cbr>\n\u003Cbr>\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) and FDA regulations. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache &amp; Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs &amp; Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>\u003Cbr>\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\u003Cbr>\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\u003Cbr>\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Anti-Viral”\u003C\u002Fu>\u003Cbr>\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Anti-Viral”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Appendix Support”\u003C\u002Fu>\u003Cbr>\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\u003C\u002Fu>\u003Cbr>\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Blood Pressure Normalizer”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\u003Cbr>\n• “It is a strong anti bacterial agent...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Brain Tune-Up”\u003C\u002Fu>\u003Cbr>\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\u003Cbr>\n• “Protects the brain from damage”\u003Cbr>\n• “Alleviates stress, anxiety, and depression”\u003Cbr>\n• “Improves memory and mood in Alzheimer’s patients”\u003Cbr>\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\u003Cbr>\n• “Can Help Fight Inflammation.”\u003Cbr>\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\u003Cbr>\n• “Can Reduce Anxiety.”\u003Cbr>\n• “Can Treat Depression.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Cardiovascular System”\u003C\u002Fu>\u003Cbr>\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Headache &amp; Pain Relief”\u003C\u002Fu>\u003Cbr>\nOn the “Headache &amp; Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Headache &amp; Pain Relief”\u003Cbr>\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Healthy Mommy Healthy Baby”\u003C\u002Fu>\u003Cbr>\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Quit Smoking”\u003C\u002Fu>\u003Cbr>\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Quit Smoking”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HyperThyroidism” (also referred to as “HyperThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\u003Cbr>\n• “For an overactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HypoThyroidism” (also referred to as “HypoThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\u003Cbr>\n• “For an underactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Mucus Release”\u003C\u002Fu>\u003Cbr>\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Parasite Cleanse”\u003C\u002Fu>\u003Cbr>\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Parasite Cleanse”\u003Cbr>\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“ResErection Extra Strength w\u002F Yohimbe Bark”\u003C\u002Fu>\u003Cbr>\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Tumor Release” (also referred to as “Tumor &amp; Cyst Support”)\u003C\u002Fu>\u003Cbr>\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Tumor Release” or “Tumor &amp; Cyst Support”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\u003Cbr>\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Un-Vax”\u003C\u002Fu>\u003Cbr>\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Venereal Defense”\u003C\u002Fu>\u003Cbr>\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Venereal Defense”\u003Cbr>\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\u003C\u002Fu>\u003Cbr>\nOn the “Womb Care Cramp Relief &amp; Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Womb Care Cramp Relief &amp; Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\u003Cbr>\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\u003Cbr>\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Lungs &amp; Respiratory”\u003C\u002Fu>\u003Cbr>\nOn the “Lungs &amp; Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003C\u002Fp>\n\n\u003Cp>• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)].\u003C\u002Fp>\n\n\u003Cp>With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&amp;C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>b. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>c. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>We note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\u003C\u002Fp>\n\n\u003Cp>You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and “Lungs &amp; Respiratory” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\u003Cbr>\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\u003Cbr>\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\u003Cbr>\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\u003Cbr>\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for weighing or measuring each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the weight or measure of each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for adding the component to the batch; and\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the addition of components to the batch;\u003Cbr>\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\u003Cbr>\n&nbsp; &nbsp; o The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\u003Cbr>\n&nbsp; &nbsp; o An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\u003Cbr>\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\u003Cbr>\n&nbsp; &nbsp; o Reviewed the batch production record [21 CFR 111.260(l)(1), including:\u003Cbr>\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\u003Cbr>\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\u003Cbr>\n&nbsp; &nbsp; o Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\u003Cbr>\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\u003Cbr>\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\u003C\u002Fp>\n\n\u003Cp>Once have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\u003C\u002Fp>\n\n\u003Cp>Specifically, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache &amp; Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\u003C\u002Fp>\n\n\u003Cp>2. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\u003Cbr>\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\u003Cbr>\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\u003Cbr>\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\u003C\u002Fp>\n\n\u003Cp>3. Your Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>,, “Headache &amp; Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\u003C\u002Fp>\n\n\u003Cp>4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache &amp; Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\u003Cbr>\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\u003Cbr>\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\u003Cbr>\n• The Headache &amp; Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\u003C\u002Fp>\n\n\u003Cp>5. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We offer the following additional comments:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMaria S. LeMay-Bey, Owner\n\nRecipient Title\n\nIsaiah Orton-Bey, Owner\n\nMoorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\n\n16136 W. 7 Mile Road\n\nDetroit, MI 48235\n\nUnited States\n\nMoorherbs13@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nCMS Case #655674\n\nAugust 1, 2023\n\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and FDA regulations. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache & Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs & Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\n\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\n\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\n\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\n\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\n\n“Anti-Viral”\n\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Anti-Viral”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\n\n“Appendix Support”\n\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\n\n“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\n\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Blood Pressure Normalizer”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\n\n• “It is a strong anti bacterial agent...”\n\n“Brain Tune-Up”\n\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\n\n• “Protects the brain from damage”\n\n• “Alleviates stress, anxiety, and depression”\n\n• “Improves memory and mood in Alzheimer’s patients”\n\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\n\n• “Can Help Fight Inflammation.”\n\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\n\n• “Can Reduce Anxiety.”\n\n• “Can Treat Depression.”\n\n“Cardiovascular System”\n\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\n\n“Headache & Pain Relief”\n\nOn the “Headache & Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Headache & Pain Relief”\n\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\n\n“Healthy Mommy Healthy Baby”\n\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\n\n“Quit Smoking”\n\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Quit Smoking”\n\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\n\n“HyperThyroidism” (also referred to as “HyperThyroid Support”)\n\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\n\n• “For an overactive Thyroid”\n\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\n\n“HypoThyroidism” (also referred to as “HypoThyroid Support”)\n\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\n\n• “For an underactive Thyroid”\n\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\n\n“Mucus Release”\n\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\n\n“Parasite Cleanse”\n\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Parasite Cleanse”\n\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\n\n“ResErection Extra Strength w\u002F Yohimbe Bark”\n\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\n\n“Tumor Release” (also referred to as “Tumor & Cyst Support”)\n\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Tumor Release” or “Tumor & Cyst Support”\n\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\n\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\n\n“Un-Vax”\n\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\n\n“Venereal Defense”\n\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Venereal Defense”\n\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\n\n“Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\n\nOn the “Womb Care Cramp Relief & Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Womb Care Cramp Relief & Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\n\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\n\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\n\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\n\n“Lungs & Respiratory”\n\nOn the “Lungs & Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. 321(p)].\n\nWith certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nThe dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\n\n1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nb. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nc. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nWe note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\n\nYou must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\n\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on (b)(4) with lot #(b)(4), “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on (b)(4) with lot #(b)(4), and “Lungs & Respiratory” manufactured on (b)(4) with lot #(b)(4), were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\n\n• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\n\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\n\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\n\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\n\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\n\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\n\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\n\n The initials of the person responsible for weighing or measuring each component used in the batch;\n\n The initials of the person responsible for verifying the weight or measure of each component used in the batch;\n\n The initials of the person responsible for adding the component to the batch; and\n\n The initials of the person responsible for verifying the addition of components to the batch;\n\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\n\no The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\n\no An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\n\no The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\n\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\n\no Reviewed the batch production record [21 CFR 111.260(l)(1), including:\n\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\n\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\n\no Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\n\no Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\n\no Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\n\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\n\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\n\nWe have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\n\nOnce have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\n\nSpecifically, on (b)(4), during the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the (b)(4) plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nMisbranded Dietary Supplements\n\nIn addition, your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache & Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache & Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\n\n2. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\n\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\n\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\n\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\n\n3. Your Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”),, “Headache & Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\n\n4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache & Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\n\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\n\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\n\n• The Headache & Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\n\n5. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nWe offer the following additional comments:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\n\nYour response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast Division 6","Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.","moorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-10-26T08:09:27.900006+00:00","2023-09-19","Division of Human and Animal Food Operations East VI","Maria S. LeMay-Bey, Owner","2026-08-20T00:39:30.007+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-08-01",7,{"510k":164,"classification":165,"enforcement":166,"event":167,"event_backfill":168,"pma":169,"warning_letter":170},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]